Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study
Status:
Completed
Trial end date:
1998-01-01
Target enrollment:
Participant gender:
Summary
A previously published, placebo-controlled, head-to-head comparator study found eletriptan to
have superior efficacy to oral sumatriptan 100 mg in treating a single acute migraine attack.
The goal of the current study was to extend the findings of that study by examining the
efficacy of eletriptan compared with both 50- and 100-mg doses of sumatriptan; and to
evaluate the comparative efficacy of eletriptan and sumatriptan across additional important
clinical outcomes. In particular, early response (at 1 hour), sustained response (without
need for additional treatment) at 24 hours, and consistency of response across multiple
attacks were examined.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.